Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells $633,275.16 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 20,356 shares of the company’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $31.11, for a total value of $633,275.16. Following the completion of the transaction, the insider directly owned 21,479 shares in the company, valued at $668,211.69. This represents a 48.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

CSTL opened at $32.03 on Friday. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. The firm has a market cap of $978.52 million, a PE ratio of -48.53 and a beta of 0.98. The business has a fifty day simple moving average of $23.77 and a 200-day simple moving average of $26.20. Castle Biosciences, Inc. has a fifty-two week low of $17.72 and a fifty-two week high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The company had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. As a group, equities analysts predict that Castle Biosciences, Inc. will post -1.29 EPS for the current fiscal year.

Key Castle Biosciences News

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and reiterated a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth outlook and indicates potential upside from recent trading levels. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle Biosciences’ latest earnings exceeded expectations. Revenue was $99.86 million versus the $86.23 million consensus estimate, while the company reported a per-share loss of $0.07 compared with the expected $0.41 loss. Although CSTL remains unprofitable, the narrower-than-expected loss and stronger revenue support an improving operating outlook.
• Neutral Sentiment: Institutional investors own approximately 92.6% of CSTL’s shares. Recent purchases or stake increases by firms including AQR Capital Management, Amundi, Legal & General and Mirae Asset may provide shareholder support, but these ownership changes are not necessarily immediate trading catalysts.
• Negative Sentiment: Several company insiders disclosed sizable stock sales. Derek J. Maetzold sold more than 39,000 shares for approximately $1.21 million in August 4–5 transactions, while COO Kristen Oelschlager sold 8,586 shares worth about $256,000. Tobin W. Juvenal separately sold 1,301 shares for roughly $50,000. The sales reduced the insiders’ positions and could pressure sentiment, particularly following CSTL’s recent advance. However, all of the reported transactions were executed under pre-arranged Rule 10b5-1 trading plans, making them a less definitive bearish signal. Castle Biosciences insider sales

Institutional Investors Weigh In On Castle Biosciences

A number of large investors have recently bought and sold shares of the business. Amundi raised its holdings in Castle Biosciences by 15,811.5% during the first quarter. Amundi now owns 4,137 shares of the company’s stock valued at $79,000 after buying an additional 4,111 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Castle Biosciences by 548.9% during the 1st quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock worth $2,743,000 after acquiring an additional 115,907 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Castle Biosciences by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after acquiring an additional 655 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in shares of Castle Biosciences by 10,592.0% during the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after acquiring an additional 2,648 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Castle Biosciences by 34.7% during the 2nd quarter. Legal & General Group Plc now owns 34,908 shares of the company’s stock valued at $713,000 after acquiring an additional 8,992 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

CSTL has been the subject of several recent analyst reports. BTIG Research raised their target price on shares of Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Canaccord Genuity Group reduced their price target on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Robert W. Baird set a $36.00 price objective on shares of Castle Biosciences in a research note on Friday, July 31st. Weiss Ratings raised shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Finally, KeyCorp set a $35.00 target price on Castle Biosciences in a report on Friday, May 29th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.